Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

• •Histologically or cytologically confirmed locally advanced or metastatic solid tumor for which there is no curative treatment
• •No known brain metastases
• •Performance status - ECOG 0-2
• •Performance status - Karnofsky 60-100%
• •WBC at least 3,000/mm\^3
• •Absolute neutrophil count at least 1,500/mm\^3
• •Platelet count at least 100,000/mm\^3
• •Bilirubin normal
• •AST/ALT no greater than 2.5 times upper limit of normal (ULN)
• •Creatinine no greater than ULN
• •Left ventricular function at least lower limit of normal if received prior doxorubicin
• •No grade II or IV tilt-table test
• •No symptomatic congestive heart failure
• •No unstable angina pectoris
• •No cardiac arrhythmia
• •No thrombotic event within the past 6 months
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •No prior allergic reaction to compounds of similar chemical or biological composition to study drugs
• •No other concurrent uncontrolled illness
• •No ongoing or active infection
• •No psychiatric illness or social situation that would preclude study compliance
• •At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
• •Prior paclitaxel allowed
• •At least 2 weeks since prior hormonal therapy
• •No concurrent steroids or hormonal therapy except steroids to prevent hypersensitivity reactions to paclitaxel or hormonal therapy for non-disease-related conditions (e.g., insulin for diabetes)
• •At least 4 weeks since prior radiotherapy
• •At least 4 weeks since prior surgery
• •Recovered from prior therapy
• •No other concurrent investigational agents
• •No concurrent combination anti-retroviral therapy for HIV-positive patients
• •No concurrent anticoagulation therapy
• •Concurrent pamidronate or zoledronate allowed for treatment of hypercalcemia or for palliation of skeletal metastases